Amneal Pharmaceuticals Inc. (AMRX)

$5.46

+0.01

(+0.18%)▲

Market is closed - opens 7 PM, 18 Apr 2024

Insights on Amneal Pharmaceuticals Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 620.04M → 616.98M (in $), with an average decrease of 0.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 11.91M → -98.64M (in $), with an average decrease of 568.8% per quarter

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 37.7% return, outperforming this stock by 45.2%

Performance

  • $5.37
    $5.51
    $5.46
    downward going graph

    1.65%

    Downside

    Day's Volatility :2.54%

    Upside

    0.91%

    downward going graph
  • $1.58
    $6.46
    $5.46
    downward going graph

    71.06%

    Downside

    52 Weeks Volatility :75.54%

    Upside

    15.48%

    downward going graph

Returns

PeriodAmneal Pharmaceuticals Inc.Sector (Health Care)Index (Russel 2000)
3 Months
4.01%
-0.5%
0.0%
6 Months
46.51%
5.9%
0.0%
1 Year
230.3%
3.1%
-1.9%
3 Years
-4.05%
14.2%
-21.8%

Highlights

Market Capitalization
1.7B
Book Value
$0.07
Earnings Per Share (EPS)
-0.48
Wall Street Target Price
7.25
Profit Margin
-3.51%
Operating Margin TTM
13.19%
Return On Assets TTM
4.67%
Return On Equity TTM
-36.06%
Revenue TTM
2.4B
Revenue Per Share TTM
13.59
Quarterly Revenue Growth YOY
1.2%
Gross Profit TTM
791.5M
EBITDA
500.8M
Diluted Eps TTM
-0.48
Quarterly Earnings Growth YOY
-0.95
EPS Estimate Current Year
0.58
EPS Estimate Next Year
0.66
EPS Estimate Current Quarter
0.09
EPS Estimate Next Quarter
0.11

Analyst Recommendation

Buy
    81%Buy
    9%Hold
    9%Sell
Based on 11 Wall street analysts offering stock ratings for Amneal Pharmaceuticals Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 32.78%

Current $5.46
Target $7.25

Company Financials

FY18Y/Y Change
Revenue
1.7B
↑ 60.88%
Net Income
-169.7M
↓ 201.24%
Net Profit Margin
-10.21%
↓ 26.43%
FY19Y/Y Change
Revenue
1.6B
↓ 2.2%
Net Income
-603.6M
↑ 255.62%
Net Profit Margin
-37.11%
↓ 26.9%
FY20Y/Y Change
Revenue
2.0B
↑ 22.51%
Net Income
68.6M
↓ 111.36%
Net Profit Margin
3.44%
↑ 40.55%
FY21Y/Y Change
Revenue
2.1B
↑ 5.08%
Net Income
20.2M
↓ 70.59%
Net Profit Margin
0.96%
↓ 2.48%
FY22Y/Y Change
Revenue
2.2B
↑ 5.67%
Net Income
-254.8M
↓ 1363.21%
Net Profit Margin
-11.52%
↓ 12.48%
FY23Y/Y Change
Revenue
2.4B
↑ 8.2%
Net Income
-84.0M
↓ 67.03%
Net Profit Margin
-3.51%
↑ 8.01%
Q3 FY22Q/Q Change
Revenue
545.6M
↓ 2.47%
Net Income
-2.4M
↓ 99.0%
Net Profit Margin
-0.44%
↑ 42.48%
Q4 FY22Q/Q Change
Revenue
609.8M
↑ 11.77%
Net Income
-5.9M
↑ 145.1%
Net Profit Margin
-0.96%
↓ 0.52%
Q1 FY23Q/Q Change
Revenue
557.5M
↓ 8.56%
Net Income
-10.1M
↑ 72.31%
Net Profit Margin
-1.81%
↓ 0.85%
Q2 FY23Q/Q Change
Revenue
599.0M
↑ 7.44%
Net Income
11.9M
↓ 218.06%
Net Profit Margin
1.99%
↑ 3.8%
Q3 FY23Q/Q Change
Revenue
620.0M
↑ 3.5%
Net Income
9.7M
↓ 18.75%
Net Profit Margin
1.56%
↓ 0.43%
Q4 FY23Q/Q Change
Revenue
617.0M
↓ 0.49%
Net Income
-98.6M
↓ 1118.89%
Net Profit Margin
-15.99%
↓ 17.55%
FY18Y/Y Change
Total Assets
4.4B
↑ 224.37%
Total Liabilities
3.5B
↑ 101.25%
FY19Y/Y Change
Total Assets
3.7B
↓ 15.78%
Total Liabilities
3.3B
↓ 3.97%
FY20Y/Y Change
Total Assets
4.0B
↑ 9.28%
Total Liabilities
3.7B
↑ 10.3%
FY21Y/Y Change
Total Assets
3.9B
↓ 1.66%
Total Liabilities
3.6B
↓ 2.41%
FY22Y/Y Change
Total Assets
3.8B
↓ 3.56%
Total Liabilities
3.6B
↑ 0.5%
FY23Y/Y Change
Total Assets
3.5B
↓ 8.6%
Total Liabilities
3.5B
↓ 3.84%
Q3 FY22Q/Q Change
Total Assets
3.9B
↓ 4.14%
Total Liabilities
3.9B
↑ 0.03%
Q4 FY22Q/Q Change
Total Assets
3.8B
↓ 1.93%
Total Liabilities
3.6B
↓ 6.78%
Q1 FY23Q/Q Change
Total Assets
3.6B
↓ 4.55%
Total Liabilities
3.5B
↓ 3.51%
Q2 FY23Q/Q Change
Total Assets
3.7B
↑ 2.05%
Total Liabilities
3.5B
↑ 1.55%
Q3 FY23Q/Q Change
Total Assets
3.7B
↓ 0.37%
Total Liabilities
3.5B
↓ 0.63%
Q4 FY23Q/Q Change
Total Assets
3.5B
↓ 5.82%
Total Liabilities
3.5B
↓ 1.23%
FY18Y/Y Change
Operating Cash Flow
250.2M
↑ 6.85%
Investing Cash Flow
-396.4M
↑ 302.19%
Financing Cash Flow
287.7M
↓ 402.77%
FY19Y/Y Change
Operating Cash Flow
1.7M
↓ 99.32%
Investing Cash Flow
-19.6M
↓ 95.06%
Financing Cash Flow
-45.8M
↓ 115.93%
FY20Y/Y Change
Operating Cash Flow
379.0M
↑ 22128.8%
Investing Cash Flow
-317.5M
↑ 1521.79%
Financing Cash Flow
131.8M
↓ 387.58%
FY21Y/Y Change
Operating Cash Flow
241.8M
↓ 36.2%
Investing Cash Flow
-194.2M
↓ 38.85%
Financing Cash Flow
-138.1M
↓ 204.79%
FY22Y/Y Change
Operating Cash Flow
65.1M
↓ 73.08%
Investing Cash Flow
-174.3M
↓ 10.23%
Financing Cash Flow
-106.6M
↓ 22.81%
Q3 FY22Q/Q Change
Operating Cash Flow
93.6M
↓ 174.55%
Investing Cash Flow
-49.3M
↑ 206.11%
Financing Cash Flow
-46.1M
↓ 298.43%
Q4 FY22Q/Q Change
Operating Cash Flow
-23.3M
↓ 124.89%
Investing Cash Flow
-11.5M
↓ 76.76%
Financing Cash Flow
-22.2M
↓ 51.95%
Q1 FY23Q/Q Change
Operating Cash Flow
139.7M
↓ 699.83%
Investing Cash Flow
-11.7M
↑ 2.36%
Financing Cash Flow
-12.9M
↓ 41.81%
Q2 FY23Q/Q Change
Operating Cash Flow
-11.3M
↓ 108.12%
Investing Cash Flow
-12.3M
↑ 4.66%
Financing Cash Flow
-12.3M
↓ 4.99%

Technicals Summary

Sell

Neutral

Buy

Amneal Pharmaceuticals Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc.
-7.78%
46.51%
230.3%
-4.05%
-56.43%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-4.63%
16.46%
27.73%
40.21%
63.9%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.25%
-2.88%
-6.68%
9.31%
9.31%
Zoetis Inc.
Zoetis Inc.
-10.35%
-12.19%
-12.37%
-8.97%
56.17%
Viatris Inc.
Viatris Inc.
-5.44%
17.92%
12.21%
-16.08%
-31.95%
Catalent, Inc.
Catalent, Inc.
-0.32%
22.03%
22.78%
-48.65%
30.48%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc.
89.83
NA
NA
0.58
-0.36
0.05
NA
0.07
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
54.74
54.74
0.44
4.69
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.79
28.79
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.48
29.48
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
226.4
226.4
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc.
Buy
$1.7B
-56.43%
89.83
-3.51%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.5B
63.9%
54.74
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.0B
9.31%
28.79
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.5B
56.17%
29.48
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.4B
-31.95%
226.4
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
30.48%
211.02
-31.77%

Institutional Holdings

  • Fosun International Ltd

    6.97%

  • Vanguard Group Inc

    4.42%

  • TPG GP A, LLC

    4.00%

  • BlackRock Inc

    2.87%

  • Rubric Capital Management LP

    2.59%

  • Nantahala Capital Management, LLC

    1.51%

Company Information

an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.

Organization
Amneal Pharmaceuticals Inc.
Employees
7850
CEO
Mr. Chirag K. Patel
Industry
Health Technology

Discover More

FAQs